Responses in evaluable patients (n = 43)
| Lymphoma subtype . | Responses . | ORR/ CR . |
|---|---|---|
| B-NHL (n = 8) | ||
| DLBCL (n = 6) | CR (2), PR (2), SD (1), PD (1) | 67%/33% |
| Other B-cell (n = 2∗) | PD (2) | |
| T/NK-NHL (n = 15) | ||
| Extranodal NK/T-cell lymphoma | CR (1), PR (4), PD (3) | 63%/13% |
| PTCL, NOS | CR (1), PR (1), PD (1) | 67%/50% |
| Angioimmunoblastic T-cell lymphoma | CR (2), SD (1) | |
| Cutaneous T-cell lymphoma | PD (1) | |
| Immunodeficiency-associated LPD (n = 10) | ||
| PTLD | CR (1), PD (2) | 50%/33% |
| Other (SLE, CVID, PI) | CR (1), PR (1), PD (1) | |
| HIV-associated lymphoma (PBL, DLBCL [2], HL) | PD (4) | |
| Hodgkin lymphoma (n = 10) | PR (1), SD (5), PD (4) | 10%/0% |
| Total (n = 43 evaluable patients) | CR (8), PR (9), SD (7), PD (19) | 40%/19% |
| Lymphoma subtype . | Responses . | ORR/ CR . |
|---|---|---|
| B-NHL (n = 8) | ||
| DLBCL (n = 6) | CR (2), PR (2), SD (1), PD (1) | 67%/33% |
| Other B-cell (n = 2∗) | PD (2) | |
| T/NK-NHL (n = 15) | ||
| Extranodal NK/T-cell lymphoma | CR (1), PR (4), PD (3) | 63%/13% |
| PTCL, NOS | CR (1), PR (1), PD (1) | 67%/50% |
| Angioimmunoblastic T-cell lymphoma | CR (2), SD (1) | |
| Cutaneous T-cell lymphoma | PD (1) | |
| Immunodeficiency-associated LPD (n = 10) | ||
| PTLD | CR (1), PD (2) | 50%/33% |
| Other (SLE, CVID, PI) | CR (1), PR (1), PD (1) | |
| HIV-associated lymphoma (PBL, DLBCL [2], HL) | PD (4) | |
| Hodgkin lymphoma (n = 10) | PR (1), SD (5), PD (4) | 10%/0% |
| Total (n = 43 evaluable patients) | CR (8), PR (9), SD (7), PD (19) | 40%/19% |
CVID, common variable immune deficiency; HL, Hodgkin lymphoma; LPD, lymphoproliferative disorder; NHL, non-Hodgkin lymphoma; PBL, plasmablastic lymphoma; PD, progressive disease; PI, primary immunodeficiency; SD, stable disease; SLE, systemic lupus erythematosus.
CD30+ B-cell lymphoma and B-LPD.